# IBA myQA SRS Detector for CyberKnife Robotic Radiosurgery Quality Assurance
## 3 Results
### Patient Plan Pre-Treatment QA
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline \multirow{2}{*}{\begin{tabular}{c} **Patient** \\ **No.** \\ \end{tabular} } & \multirow{2}{*}{**Disease**} & \begin{tabular}{c} **Description** \\ **(1 Fraction)** \\ \end{tabular} & \multirow{2}{*}{\begin{tabular}{c} **Beam** \\ **Pruning** \\ \end{tabular} } & \multirow{2}{*}{\begin{tabular}{c} **Beams** \\ **(\%)** \\ \end{tabular} } & \multirow{2}{*}{\begin{tabular}{c} **Gamma** \\ **Index** \\ **(3\%/1 mm)** \\ \end{tabular} } & \multirow{2}{*}{\begin{tabular}{c} **Gamma** \\ **Index** \\ **Improvement** \\ **(\%)** \\ \end{tabular} } \\ \hline \multirow{2}{*}{1} & \multirow{2}{*}{Meningioma} & \multirow{2}{*}{5} & No & \multirow{2}{*}{42} & 85.6 & \multirow{2}{*}{12} \\ \cline{3-3} \cline{5-6}  & & & Yes & & 95.8 & \\ \hline \multirow{2}{*}{2} & \multirow{2}{*}{Meningioma} & \multirow{2}{*}{5} & No & \multirow{2}{*}{37} & 89.1 & \multirow{2}{*}{11} \\ \cline{3-3} \cline{5-6}  & & & Yes & & 98.6 & \\ \hline \multirow{2}{*}{3} & \multirow{2}{*}{\begin{tabular}{c} Breast Cancer \\ Metastasis \\ \end{tabular} } & \multirow{2}{*}{7} & No & \multirow{2}{*}{38} & 55.3 & \multirow{2}{*}{61} \\ \cline{3-3} \cline{5-6}  & & & Yes & & 89.2 & \\ \hline \multirow{2}{*}{4} & \multirow{2}{*}{\begin{tabular}{c} Trigeminal \\ Neuralgia \\ \end{tabular} } & \multirow{2}{*}{75} & No & \multirow{2}{*}{44} & 89.3 & \multirow{2}{*}{12} \\ \cline{3-3} \cline{5-6}  & & Yes & & 100 & \\ \hline \multirow{2}{*}{5} & \multirow{2}{*}{\begin{tabular}{c} Acoustic \\ Neuroma \\ \end{tabular} } & \multirow{2}{*}{12} & No & \multirow{2}{*}{61} & 68.9 & \multirow{2}{*}{37} \\ \cline{3-3} \cline{5-6}  & & Yes & & 94.2 & \\ \hline \multirow{2}{*}{6} & \multirow{2}{*}{\
\begin{tabular}{c} Glioblastoma \\ recurrence \\ \end{tabular} } & \multirow{2}{*}{14} & No & \multirow{2}{*}{41} & 45.4 & \multirow{2}{*}{115} \\ \cline{3-3} \cline{5-6}  & & Yes & & 97.7 & \\ \hline \multirow{2}{*}{7} & \multirow{2}{*}{
\begin{tabular}{c} Trigeminal \\ Neuralgia \\ \end{tabular} } & \multirow{2}{*}{64} & No & \multirow{2}{*}{22} & 79.6 & \multirow{2}{*}{25} \\ \cline{3-3} \cline{5-6}  & & Yes & & 99.5 & \\ \hline \multirow{2}{*}{8} & \multirow{2}{*}{Metastasis} & \multirow{2}{*}{7} & No & \multirow{2}{*}{45} & 47.1 & \multirow{2}{*}{112} \\ \cline{3-3} \cline{5-6}  & & Yes & & 99.7 & \\ \hline \multirow{2}{*}{9} & \multirow{2}{*}{Sarcoma} & \multirow{2}{*}{20} & No & \multirow{2}{*}{37} & 94.6 & \multirow{2}{*}{6} \\ \cline{3-3} \cline{5-6}  & & Yes & & 100 & \\ \hline \multirow{2}{*}{10} & \multirow{2}{*}{Haemangioma} & \multirow{2}{*}{16} & No & \multirow{2}{*}{22} & 97.1 & \multirow{2}{*}{3} \\ \cline{3-3} \cline{5-6}  & & Yes & & 100 & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Patient-specific verification plans retrospectively delivered on myQA® SRS phantom. For each case the treated disease, the prescription dose, and the resulting Gamma Index passing rate are specified. As a result of beam pruning, the percent of deleted beams and the percent of improved Gamma passing rates are also reported. Patients\({}^{\prime}\) data were anonymized before handling.